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Abstract  
Translating R&D and inventive efforts into a market product is characterized by significant 
financial skills, and the ability to overcome technical and instititonal barriers. Research into 
and translation of new technologies such as biotechnology products to the market requires 
even greater resources. This paper aims to understand the key factors that foster or hinder 
the complex process of translating R&D efforts into innovative products. Different 
pathways exist in developed countries such as firm-level efforts, the use of IPs, the spin-off 
of new firms that develop new products, or a mixture of these. Developing countries differ 
substantially in the kinds of instruments they use because of their considerably weaker 
institutional environment and for this reason our framework takes a systemic and 
institutional perspective. The paper comtributes to this issue by examining systemic 
institutional barriers to commercializing biotechnology in a develping context within a 
systems of innovation framework. 
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1. Introduction 
 
Investment in scientific research often carries with it an implicit assumption of reaping the 
fruits of commercial innovation in the form of products and processes. However, the path 
from the laboratory to the market can be long and expensive and the outcome uncertain. 
Institutional and structural factors pose significant and sometime unexpected obstacles 
particularly in a global context with fast changing rules of the game. This is all the more the 
case in an innovation-driven and science-based sector such as biotechnology, which is 
characterized by idiosyncratic technical and scientific properties (Traore and Rose, 2005; 
Gregorio and Shane, 2003). Success in mastering such a technology would therefore require 
deep-going changes to existing formal and informal institutions that supported traditional 
scientific research and development (R&D) and commercialization in the past. This places a 
double burden on developing countries that are still in the process of acquiring scientific and 
technological capabilities. First they face the challenge of modernizing both the scientific and 
production structures to deal with the complex requirements of biotechnology and second 
these countries need to resolve the imperative of new institutions that define the ecology and 
dynamism of new technologies (Whitley, 2003; Pisano, 1996). 
 
There are four broad features of biotechnology that create discontinuity with extant 
scientific culture of developing countries. First, biotechnology has its roots deep in basic 
science and its rise in the west is associated with the activities of “star” scientists, the so-
called entrepreneurial scientists (Ben David, 1971; Oliver, 2004). The practice of science in 
most developing countries is relatively recent, characterized by academic migration, and 
academic entrepreneurship is hardly common as a result of rigidities in the terms of 
employment. Second, biotechnology has a strong interdisciplinary content (that fosters 
strong collaborations within the academic disciplines) and complimentarily, leads to the 
growth of networks (Powell et al, 1996) that re-defines the nature of inter-firm collaborative 
structures. Systems of innovation in developing economies are notably weak and beset with 
systemic disarticulation (Oyelaran-Oyeyinka, 2005; Cassiolato and Lastre, 2004) with poor 
links between research and industry. Third, new institutions such as venture capital and spin-
off companies that cluster around strong research-based universities are rare (Zucker et al, 
1998).  The last factor relates to a set of informal norms and practices embedded within and 
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reinforced over the long term by formal institutions such as the attitudes to intellectual 
property, the propensity to patent research results, and the nature of academic employment 
that engender little incentive to pursue commercial ventures (Lehrer and Asakawa, 2004).     
 
Among the prominent sources of knowledge within the national system of innovation are 
industrial firms, private laboratories, universities and public research institutions. While all 
these organizations have traditionally been sources of commercial technologies, universities 
and public laboratories are notable sources of inventive activities for knowledge-based new 
technologies such as biotechnology. Universities have over time been regarded as centres of 
knowledge creation and products of research that are been increasingly commercialized 
(Etzkowitz, 1998; Henderson et al, 1998)). In turn inter-organizational collaboration has 
grown with the private sector relying more on the products of scientific research from 
universities and public research institutes (Powell et al, 1996). Relatedly, there has been a 
growing pressure on universities and public research institutes to commercialize research and 
efforts have been made to understanding the different innovation pathways and what 
constraints successful inventive activity (Cohen, Nelson and Walsh, 2002). 
 
At the same time, as Laursen and Salter (2004) report in their study of university-industry 
collaboration, the role of universities in generating knowledge may have been exaggerated. 
Scholars of innovation system have emphasized the multiplicity of sources of knowledge in 
the economy and the fact that universities and public research institutes are only one of 
them. Again, the level of scientific and technological development will condition the roles 
that different actors (firms, universities, private and public laboratories) will play in the 
generation, validation and distribution of knowledge. This is due to the idiosyncratic nature 
of the process of commercialization of research. The process of innovation is path 
dependent, while its trajectory depends entirely on the context, and the capacities of myriad 
system actors (Raemer et al, 2003; Kline and Rosenberg, 1986).        
 
Several channels have been identified as important in the literature for translating research 
efforts to innovative products and processes. These include exchange of information 
between actors and organizations, technical assistance, cooperative research, licensing and 
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sale of intellectual property, spin-off of companies from research and hiring of skilled 
personnel (Traore and Rose, 2003; Reamer et. al, 2003). 
 
The context-specific nature of the process (level of technology and the quality of scientific 
and technological infrastructure) as well as the nature of institutions (the scientific culture 
and support systems) can mean that the factors that foster or hinder the translation of 
research into innovation would differ in developing and developed economies. For instance 
while patenting has received widespread attention in the literature on commercializing 
biotechnology in advanced industrialized countries (Henderson et al; Arundel, 2001; Mowery 
et al, 2001), this is not the case in developing countries. For instance, in a study that 
investigated the decisions to commercialize new technologies within a large number of 
research establishments in India, patentability of technology was ranked seventh in 
importance (Kumar and Jain, 2003). The research on which this paper draws focused on the 
research activities of a number of universities and public research institutes in Nigeria with 
the aim to understand the determinants of and barriers to translating research to innovation. 
Specifically, we try to investigate, within a comparative institutional perspective, the ways in 
which national trajectories are shaped by historical circumstances. In Africa, universities and 
public research institutes are controlled and funded largely by governments and we take this 
as our entry point of inquiry. In other words, in what ways have institutions shaped the 
observed path of scientific research to the market? Why have there been so few successes in 
taking inventions to the market in Africa? We take the case of biopharmaceutical system in 
Nigeria as a case study and our hypothesis simply is that the institutionally  determined 
policy processes have impacted significantly on the ways inventive activities travel/or do not 
travel from the laboratory to the market. 
 
The paper is divided into seven parts. The next section provides some information on the 
capacity of universities and public research institutes in the country. Section 3 presents an 
analytical framework of systemic institutional barriers to innovation efforts, within which the 
discussions presented in the remaining sections of the paper are structured. We then present 
an econometric model as well as case studies that illustrate the main propositions of the 
paper. The final section concludes. 
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2. The Capacity of Nigerian Universities and Public Research Institutions for 
Biopharmaceutical Research1 
Nigeria’s higher education institutions run various programs in the different health and 
pharmacy disciplines. Among the three categories of tertiary institutions (Universities, 
Polytechnics, Colleges of Education) only the Universities offer first degree courses in 
pharmacy. Although pharmacy is a major discipline, it offers a single first degree programme 
in almost all the Universities with the exception of University of Lagos which also offers a 
first degree programme in Pharmacology. Programmes that are relevant to Biopharmacy are 
also taught in Medicine and Veterinary Medicine and are equally offered only in the 
Universities. These courses like pharmacy at first degree level are single degree programmes. 
A total of nineteen Universities offer degree programmes in Medical Sciences and five, in 
Veterinary Medicine. Programmes in the sciences form the bulk of courses that are relevant 
to the subject discipline and a few of these are offered in the  polytechnics, monotechnics 
and colleges of education as well. 
The general objective of pharmaceutical education is “to provide competencies for 
performing all pharmaceutical services in Nigeria”. The course curriculum includes basic 
sciences and preclinical sciences and professional studies. Basic Sciences refers to courses in 
the physical and biological sciences as well as mathematics which are pre-requisites for the 
pre-clinical and professional courses such as Anatomy, Biochemistry, Physiology, Histology, 
and Microbiology. In Professional Studies and Training, the variety of courses include 
Biomedical/Pharmaceutical Sciences, Management of Pharmaceutical Sciences and Clinical 
Pharmaceutical Sciences. This includes clinically applied courses in pharmacy practice based 
on the pharmaceutical and biomedical sciences, such as biopharmaceutics, pharmacokinetics 
and pharmacotherapeutics. This also includes supervised training in appropriate in-patient 
and out-patient environment under the general title of Clinical Pharmacy. 
                                                          
1  The information contained in this section is based on the 2004 survey conducted by the Nigerian 
National Universities Commission (NUC). They can be found in a report titled: Needs Assessment of the 
Nigerian Labour Market, NUC, 2004. 
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The different governments invested relatively heavily in the educational system in Nigeria. The 
number of Universities in Nigeria increased from one in 1948 to two in 1960, seven in 1970, 
seventeen in 1980, and thirty-one in 1990 and currently, there are over forty universities. 
The Nigerian National Policy on Education placed a strong premium on Science and 
Technology and states inter alia; a greater proportion of expenditure on university education 
shall be devoted to Science and Technology, and also provided that not less than 60% of 
places shall be allocated to science and science-oriented courses in the conventional 
universities and not less than 80% in the universities of Technology. Several medical 
colleges, specialist teaching hospitals, science centers, and Research and Development 
Institutes (RDIs) were built. The private sector established technical and technological 
training institutes and colleges to produce middle and high-level man-power. However 
several factors have conspired to truncate the basic objectives of a science policy that sought 
to build a dynamic science-driven industrial sector. 
 
 The military governments over a period of more than three decades invested little on S&T 
infrastructure and as employment opportunities diminished, many scientists and engineers 
migrated abroad. The introduction of the Structural Adjustment Programme (SAP) in 1986 
led to a dismantling of state-controlled sectors of which the universities and RDIs are a part.  
 
  At the same time enrolment in universities grew, a result of the “Universal Primary 
Education Scheme” which began in 1976 releasing its first products for University 
admission in 1988.2 The annual growth rate for the nineties averaged 12%. The mean 
graduate output for pharmacy as a discipline since the early 1980s is 398 per annum. A total 
of 187,530 graduates have been trained within the same period in programmes relevant to 
Biopharmacy. 
  
Public research institutes (hereafter, PRIs) are fully state-funded and devoted to research into the 
use of local resources with the main objective of adding value through R&D and processing. 
PRIs have been established for different sectors, namely in agriculture, chemicals, new 
materials and recently, in space and biotechnology. PRIs have been very important due in 
                                                          
2 The take-off enrolment of 210 was recorded for all disciplines in 1948 for University College Ibadan, the 
Premier University. This went up to 23, 000 in the six Universities in 1962. By 1996, the total student 
enrolment figure had risen to 234,581 for 37 Universities and by March 2002 it shot up in excess of 526,780.  
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part to the weak capacity of private R&D, low level of entrepreneurship that put pressure on 
PRIs to fill this void. We selected five PRIs for close examination in this study and they are: 
the Sheda Science and Technology Complex (SHETSCO), National Institute for 
Pharmaceutical Research and Development (NIPRID), the National Veterinary Research 
Institute (NVRI), the National Institute for Medical Research (NIMR), and the National 
Centre for Genetic Resources and Biotechnology (NACGAB). 
 
 The areas of focus of the institutes are shown in the Tables 1 and 2 , which equally reveal 
distinct disciplinary specialization. NAGRAB concentrates exclusively on the preservation of 
Nigeria’s genetic resources (100%), NVRI devotes its attention to animal-based research 
(90%), NIPRID research is in medicine particularly ethno-medicine (70%); and true to its 
mandate, SHETSCO’s activities span the three areas of bioprocessing: industrial (71.4%), 
agriculture (57.1) and medical biotechnology (71.4%).  SHETSCO’s work in bio-processing 
also includes the development of a gene bank for yeasts. An important focus of the research 
at the SHETSCO Complex is the transformation of three local staples, namely banana, 
plantain and cassava using agricultural biotechnology and the work here builds on what the 
International Institute for Tropical Agriculture (IITA), situated in Ibadan has been doing in 
order to create superior products through the use of DNA techniques. The institute plans 
collaboration with the International Agricultural Research Institute (IARI) for staff training 
on this project. At the time of the survey visit, an expert on banana from the IITA was 
visiting the SHETSCO Complex. SHETSCO has also been contracted by one of the 
southern states, the Bayelsa State government to carry out some work on the propagation of 
local staples using tissue culture.   
 
The pressure to raise additional revenues has forced PRIs and universities to increasingly 
engage in a variety of activities that supplement their financial allocations from the 
government. They are in the main, consulting, knowledge transfer to industry through 
formal and informal channels, and spin-off firms from commercializing research. We sought 
to know how the different PRIs divide their time in respect of research, which is their 
primary mandate, and other activities. Apart from SHETSCO, all the institutes are engaged 
in significant amount of training in addition to research. All the PRIs devote some effort and 
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time to consultancy, as a way of augmenting their finance, testing and laboratory services, 
production and contract manufacturing.    
 
There is a lack of systematic data on the extent and depth of biotechnology research within 
the biopharmaceutical system of innovation. We asked respondents to indicate the broad 
areas as well as the tools of biotechnology that they presently use and the time and human 
resources involved. Bioprocess technologies are widely applied at NIPRID and SHETSCO 
(57.2% and 60% of activity respectively) followed by recombinant DNA in NIPRID and 
tissue culture in SHETSCO. This confirms some of the earlier but partial survey of biotech 
activities by Alhassan (2000), which concluded that cell and tissue culture dominates the 
activities of actors in this system although his study focused only on agricultural 
biotechnology. This present study shows that while research using cell and tissue culture is 
relatively widespread, PRIs are also applying bio-processing and DNA techniques although 
limited by facilities and equipment to a few number of researchers. For instance, NIPRID 
devotes on average 20% of its resources to aspects of recombinant DNA and 61.3% to 
molecular diagnostics and less than 20% of financial resources are devoted to cell and tissue 
culture. This is not surprising given that the mandate of NIPRID is medical biotechnology. 
SHETSCO on the other hand, has been engaged more in agricultural biotechnology despite 
the relatively advanced nature of their laboratory. There are two reasons for this. First, the 
facilities are only partially completed and for most part, scientific facilities in SHETSCO are 
utilized at less than full capacity due to poor power supply and incomplete equipments. 
Secondly, there has been a consistent under-funding of SHETSCO as a result of which 
much of their research activities have been donor-driven. For instance, research activities 
applying cell and tissue culture to improve plant and crop varieties are being sponsored by 
USAID and a state government which contracted the Complex to carry out study on micro-
propagation of banana for possible mass production.   
 
 Table 1: PRIs  Area of Focus (%) 
Institutions Industrial 
research 
Agricultural 
research 
Medical 
Research 
Others
1. NAGRAB3   
100.0 
  
                                                          
3  The questionnaire by NAGRAB was filled in by the director of the agency and is the only place where 
we administered only one questionnaire. 
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2. NVRI  
10.0 
 
90.0 
 10.0  
3. NIPRD  
10.0 
  
70.0 
 
30.0 
4. SHETSCO  
71.4 
 
57.1 
 
71.4 
 
Source: Field work (2004) 
  
 
Table 2: Major Activities of Institutes 
ActivitiesÆ 
Institutions 
Research Teaching Consultancy Production T&L 
services 
Contract 
Manu. 
Others
NACGRAB  
100.0 
  
100.0 
 
100.0 
 
100.0 
 
100.0 
 
NVRI  
90.0 
 
80.0 
 
60.0 
 
70.0 
 
70.0 
 
70.0 
 
10.0 
NIPRID  
90.0 
 
70.0 
 
60.0 
 
60.0 
 
60.0 
 
60.0 
 
SHETCO  
85.7 
 
14.3 
 
28.6 
 
42.9 
 
42.9 
 
42.9 
 
Source: Authors survey (2004) ;T&L = Testing and laboratory services  
  
 
 
  
   
2.1 Institutional Shocks and Emergence of Institutional Inertia4 
While organizations may be subjected to strong inertia pressures, lack of perceptible change 
may not necessarily mean that an organization is stagnating. There could be two possibilities. 
First, an organization may respond too slowly relative to the changes in the local, national or 
global contexts. This might well be the case with much of the perceived slow speed of 
commercialization of inventions in African universities and research institutes. Second, 
organizations may be subjected to too much and too strong structural inertia relative to their 
internal capabilities to make on-going changes inadequate. 
 
The academic system in Nigeria inherited habits and norms that tend to be at variance with 
current global realities such as faster cycles of innovation activities. Again, the system has 
                                                          
4  This section benefits from Oyelaran-Oyeyinka, B.(2006), Learning To Compete in African Industry: 
Institutions  and Technology for Development, UK: Ashgate Publishing.   
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confronted dissipative forces arising in the main from rapid structural reforms for instance that 
re-focused the attention of universities and PRIs to non-scientific activities that made real 
substantive changes difficult or impossible. For instance, reform "conditionalities" such as 
forced budgetary cuts led to widespread closures of universities in Nigeria through strikes and 
created instability in other levels of the educational sector. Faced with this situation, 
universities were unable to pay the desired attention to developing necessary knowledge and 
physical infrastructure that over time suffered decay. Research institutions had to cut back on 
necessary, but unaffordable imports and technical services all too suddenly due to massive 
devaluation of local currencies. Subsequent reduction in journal subscription and laboratory 
facilities resulted in declining standards of research and training. Figures 1 and 2 show the 
separate cases of declined spending by the Nigerian government on students and the overall 
picture in SSA. 
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Figure 1: Government expenditure on education in Nigeria 
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Figure 2: Government Expenditure on Tertiary Education per student in SSA (constant 
1990US$) 
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Commitment to public research can be assessed from the financial allocation to PRIs over 
time. Table 3 shows the evolution of public expenditure on science and technology in the 
period of 1980 to 1992 in Nigeria. The peak was 1983 and even at this stage, it was far short 
of the levels with comparative resource endowment, and less than half the target of 1% R&D 
as percent of GDP specified by the Lagos Plan of Action. This level of allocation is in fact 
only indicative because we do not have the breakdown for the different expenditure items 
such as direct allocation to laboratories and salaries, for instance.   
 
Available resources for S&T investment in other African countries are not different 
significantly in orders of magnitude. For instance, the expenditure on R&D as percent of 
GDP for sub-Saharan Africa (SSA) is on average 0.29% (1990 figure), while that of South 
Africa, the most industrial country in the continent is around 0.6%. Comparatively, the 
average for Latin America is 0.4%, and East Asia ,2.05%5.    
   
Table 3: Public Expenditure on Science and Technology in Nigeria  
(as % of GDP) 
1980 1981 1982 1983 1984 1985 1986 1990 1991 1992 
0.18 0.41 0.29 0.43 0.13 0.1 0.11 0.08 0.07 0.05 
Source: UNESCO Yearbook, 1994 
 
3. Systemic Institutional Barriers and Innovative Efforts: An Analytical framework 
The main actors in the biopharmaceutical system of innovation that interact, to collaborate 
based upon their respective competencies are public research institutions; university 
departments such as microbiology, botany, pharmacy, medicine and natural sciences, private 
firms involved in biotechnology; international research institutions; local and indigenous 
communities; traditional medicine practitioners and hospitals; and, government departments 
and agencies involved in certification and regulation. A framework is depicted in figure 3. 
                                                          
5  While R&D expenditure gives an indication of research commitment, other measures are required to 
fully paint a picture of the national innovation capacity such as ratio of scientists and engineers, quality of 
national laboratories and so on. 
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The key issues are those of learning efficiency, local orientation, national innovation policy, 
sources of knowledge exchange and infrastructure. 
Figure 3: Analytical Framework 
 
Source: Oyeyinka and Gehl Sampath, 2004 
 
In this framework, the competencies of actors in translating inventions into innovations is 
linked to four main factors: the role of national innovation policies, learning and learning 
efficiency of the actors, mechanisms of transferring products and processes into the local 
market, local and international orientation of actors. 
3.1. National Innovation Policies 
Institution 
Knowledge 
Base
Learning Effectiveness
Infrastructure Finance 
Research 
organization/ 
university 
Efficiency Effectiveness 
Institutional 
effectiveness 
International 
collaboration 
National 
Innovation 
Policy 
Local 
orientation 
Inputs/markets 
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Innovation policy differs from orthodox science and technology policy in two main respects. 
First, it seeks above all to promote systemic dynamics within the national economy rather 
than focusing on one or the other set of actors. Second, it encompasses a wide array of 
policies that are rooted in the social system in which the policy is operational.  The overall 
objective of innovation policy is to generate systemic efficiency. A considerable number of 
late followers have attained a high level of per capita income and have succeeded in moving 
into high-value manufactured export goods such as electronics. A number of systemic 
instruments have emerged to be crucial in such transitions, including clustering policies, 
collaborative R&D and science parks (Mathews and Cho 2000; Lall 2001; Amsden 1989; 
Amsden and Chu 2004; Oyelaran-Oyeyinka and McCormick, 2006). However, much of the 
successful cases of innovation policy practice are found in East Asia as well as some of the 
high performing Asian economies, with some Latin American economies notably, Brazil, 
Argentina, and Chile. The economic performance of these successful latecomers therefore 
rests in part on their policy-induced, efficient, high-quality technology institutions; highly 
skilled engineers and professionally managed enterprises, (Amsden, 1989). 
African countries have been slower in recognizing the need to address the systemic aspects 
of policies. The major weakness of the innovation policies of African states has been the 
neglect of the evolutionary character of technological advance in long-run economic 
development. While governments have established ministries of science and technology 
(S&T), most have little interaction with other economic policy ministries and R&D agencies 
that are in turn isolated from the private sector. This pattern of development inadvertently 
alienates the policy making machinery from mainstream policy making. Again, the supply-
side of knowledge and policy is largely disconnected from the demand side. Governments 
for instance have set little store on using procurement policy to stimulate demand for 
innovation. The formulation and implementing of industrial policy is also quite separate 
from the S&T policy making process. In effect, national technological infrastructure tend to 
give little support to domestic firms that would benefit from the evolutionary process of 
technological deepening through learning that is the hallmark of dynamic latecomers. In 
sum, the legacy of past practices of doing S&T policy, rather than an emphasis on 
innovation policies, and the weak bureaucratic capacity to manage a modern system of 
innovation, have combined to severely limit the administrative and institutional capabilities 
of the African State.  
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What this means is that innovation systems are shaped by fundamental social processes 
outside the domain of the firm at the material time.6 Observed patterns of production and 
innovation cannot be explained in purely social, economic or technological terms. 
Innovation systems are rooted within localized learning organizations even in the context of 
a globalizing learning context. The idiosyncratic character of firms and organizations is 
developed by the efforts of individual engineers and managers through an evolutionary 
process, in which the state remains an important coordinator. Since tacit knowledge 
constitutes an important asset of organizations, firms remain rooted in local socio-economic 
milieu.  
 
3.2 Technological Learning and Learning Efficiency 
According to Dodgson, (1991), “…[f]irms build and supplement their knowledge bases 
about technologies, products and processes, and develop and improve the broad skills of 
their work force through various learning processes”. Hence learning is crucial to enterprise 
growth and survival because it is an important avenue for the acquisition of capabilities.  
  The learning processes and performance of a firm is conditioned significantly by the 
selection environment, which could be the result of market or non-market selection resulting 
from the demand and supply conditions in markets, as well as from the institutional and 
policy context. Selection exerts powerful influence at another level, which is as a determinant 
of the sources of learning. A learning trajectory as Malerba argues, is a result of the 
structures of learning which in turn generates the pattern of observed innovation (Malerba, 
1982; Metcalfe, 1997), There are diverse sources of learning apart from doing R&D which 
include learning-by-doing, learning-by-using and learning-by-interacting. Other forms of 
building up what (Edquist, 2001) called structural capital (knowledge capital controlled at the 
organization level than by individuals) include training and hiring skilled individuals. 
Generally, learning processes are key determinants of innovative activities while institutions 
are the repositories of knowledge. This is particularly so for tacit, non-codified knowledge at 
the organizational and firm-level. As North (1996) puts it: 
                                                          
6  The French centralized systems of innovation has its roots in the historical decision by kings seeking 
means of control and taxation, and the subsequent nation building through a revolution. 
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 The speed of economic change is a function of the rate of learning, but the direction of that change is 
a function of the expected payoffs to acquiring different kinds of knowledge (North, 1996, p. 346; 
emphasis added). 
In order to develop a new product or process within an organization, firms engage in 
learning as much through internal R&D and production as through collaborative efforts and 
competition. There are among others, two broad reasons for this. Firstly, all societies no 
matter their level of development need to process and use knowledge of one kind or 
another. This knowledge does not reside only within the organization. As Metcalfe (2003) 
observes, “…[e]very economy, always and everywhere, is a knowledge economy; for social 
systems and economies as social systems, could not be arranged otherwise”. The second 
reason is that knowledge growth, validation and transfer is a socially distributed process, 
mediated by institutions (Lundvall and Johnson, 1994; Metcalfe 2003). However, institutions 
of knowledge in developing countries are relatively weak and in most cases absent, because 
small firms, universities and PRIs often lack resources for innovation. 
Therefore, understanding the nature and character of a particular national innovation system 
requires one to examine the processes and efficiency of the learning process within that 
system. As Lundvall (1992, p. 1) puts it “…[t]he most fundamental resource in the modern 
economy is knowledge and, accordingly, the most important process is learning”. Systemic 
cohesion is a key attribute of well functioning system and as such ongoing interactive 
processes should be able to accommodate the unpredictable, emergent qualities of 
innovation and new knowledge production. Since much of technological knowledge contains 
elements of ‘tacitness’, making it difficult or very costly to effectively communicate the full 
range of skills and knowledge required to execute complex tasks, recipients can never hope 
to obtain all information from codified sources such as blue prints and manuals.  
 
4. Institutions Supporting Knowledge Transfer 
Broadly speaking, institutions perform three main tasks, namely, attenuate uncertainty, 
resolve conflicts and provide incentives (Edquist, 1997). The notions of uncertainty and 
appropriability are central to the process of innovation. According to (Arrow 1962; Nelson 
1959), the key source of technological advance, which is research and development (R&D) 
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suffers from the twin failures of uncertainty and low appropriability. Firms will under invest 
in knowledge generation because social rates of return from R&D supersede private returns. 
The outcomes of inventive activities are inherently uncertain because projects might run into 
cost and time overruns and commercial outcomes are difficult to predict. Therefore, a firm 
will place a low premium on a potentially socially useful innovation that, from the judgement 
of the firm, might be costly, risky, and promise low future returns.  
 However, institutions, partially due to historical reasons, could constitute systemic 
institutional barriers to the process of innovation. We consider two broad ways in which this 
could happen, and they are: institutions that provide a variety of incentives, and institutions 
that support collaborative learning. Institutions that provide incentives include those 
established for regulation of the labour market, the terms of employment of university 
lecturers or employment of scientists in public laboratories. They also include other 
institutions that are set up to foster organizational learning and establish various 
infrastructures to commercialize inventions. These include collaborative R&D funds, 
exchange of personnel and contract research. 
The main competencies of the biopharmaceutical innovation system comprise scientific 
infrastructure, trained personnel, research inputs, such as genetic resources and traditional 
knowledge. The availability of scientific infrastructure in universities and public research 
institutes determine the scope for specialization in any or all of the stages of this research, 
both physical and human capital-related, which are specific for each one of its sub-stages. 
Trained personnel from various disciplines, some as diverse as physics, informatics and 
optical sciences are required to facilitate optimal biotechnological innovation, in addition to 
those in genetics, biochemistry, immunology, cell biology, pharmacy and general medicine 
(Chiesa and Toletti, 2004).  
4.1. Institutions and Innovation Incentives  
The dynamics of reward systems and collaboration incentives are an important mechanism 
that shape the ways inventions are translated to the market although researchers interviewed 
in our survey tended to rank lack of facilities and research funding as the most critical factor 
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that affect university performance. Incentive systems tend to develop from more 
fundamental institutional roots such as labour laws, commercial laws and even a country’s 
constitution. Terms of employment and work environments, both tangible (research and 
teaching facilities) and intangible (possibilities for institutional collaboration, quality of 
networks and colleagues) play a pivotal role in retaining skilled professionals. Different 
countries have different incentives, a good example being the possibility of conferring 
ownership of patents on individual researchers in German law, thereby granting them 
intellectual property on their inventions (Giesecke, 2000). As a result, academics have no 
obligation to share the outcome of research with their employers, and the motivation to file 
patents is also weakened because individual scientists have to do it on their own. In contrast, 
the US system facilitates the “Office of Technology Transfer” to assist scientists in the 
process of finding commercial partners, in return for a share of the royalty. In this wise, the 
office of technology transfers (OTTs) are operated as profit centres in the US and in the 
process closer university-industry relations are structured.  
There are a number of mechanisms and channels for the effective transfer of knowledge 
between organizations. The adoption and mastery of a technology requires the acquisition of 
knowledge about a set of procedures, understanding of why the procedure work and skill in 
putting them in use. Specifically in the context of academic-industry exchange, several 
channels have been identified for knowledge transfer and learning, which include 
publications, mobility of scientists and engineers, informal networks, cooperative R&D, 
facility sharing, research training (e.g. capacity development at PhD level, international and 
local exchange of staff), contract research, intellectual property rights (licenses, patents, 
copyrights), and academic entrepreneurship (Brennenraedts et al, 2006). 
Taking a capability view of the organization means that learning efficiency that improves 
performance will tend to display durability (learning should endure), and appropriability (the 
ability of a firm to profit from learning) (Peteraf, 1993). 
 
4.2 Institutional Infrastructure Incentives  
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Translating research to innovation requires a system of knowledge infrastructure of certain 
quality. It provides the organizational incentive for the long and often complicated process 
of innovation. Knowledge infrastructure is required at the most basic level of education 
(training scientists and engineers), as well as at the level of public scientific research and 
development. These roles are fulfilled by state-based institutions, mainly the universities and 
PRIs (also known as public research organizations, or PROs). One of the fundamental 
functions of these institutions is R&D-based learning that creates the absorptive capacity of 
nations (Teubal, 2001).7 The state has historically played a leading role in both the early 
“industrializers” as well as in the more recent dynamic economies such as Taiwan and South 
Korea (Mowery 2005). For example, the role of universities as a source of trained personnel 
and streams of scientific and technological knowledge has received considerable attention. 
Universities are also a facilitator, for example, through the mobility of scientists between 
university and industry, diffusion of new knowledge, and human capital. In sum, for more 
than a century, states have recognized and used the institutions of universities and PRIs as a 
vehicle of catch-up in respective periods, although the roles of the institutions expectedly 
differ/ evolve with the stage of development. “Institutional differentiation” is required to 
generate the right kinds of knowledge and skills in an economy, by which Mowery (2005) 
means the mix of tertiary but non-university establishments such as polytechnics, 
community colleges and other forms of technical institutes. This mix of institutional 
structures and the variety of funding arrangements that support them have contributed to 
the successful response of the system to labour-market demands for skills and knowledge in 
the developed countries. 
  
 4.3 Institutions Promoting Collaborative Learning 
The different stages of biopharmaceutical research still engage the same core technologies 
such as those required for pre-clinical and clinical testing, marketing and manufacturing, 
remain the same as in the case of traditional drug research (Madhok and Osegowitsch, 2000) 
despite the changes introduced by biotechnology. Each one of these stages and sub-stages is 
                                                          
7 Teubal considers two mutually reinforcing phases, namely inter-firm learning about R&D (applicable largely 
to the early innovation phase such as searching for markets and technical information, identifying and 
generating new projects, learning to screen, evaluate, and choose new projects, and learning to manage the 
process); and collective learning, which in addition to inter-firm learning, includes managerial and marketing 
functions that are crucial to the innovation process. 
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earmarked by specialized actors and competencies, and this underscores the central role of 
collaboration in biotechnology-based drug research. 
Academic-industry collaboration does not just happen. The institutional barriers to natural 
collaboration are considerable. First, the nature of knowledge generation and transfer 
between universities and PRIs and industry is complex, highly systemic and context-specific, 
particularly as a result of the significant but hardly acknowledged tacit content of scientific 
skills required. Second, there is a wide gap between the motivation, scope and purpose of 
academic research as opposed to industrial research and production. This complicates the 
transfer process and restricts the scope for policy incentives (Dasgupta and David, 1994). 
Third, firms seek external collaboration for purposes of learning because autonomous 
efforts are costly and innovation outcomes are uncertain. Firms therefore focus on core 
activities and prefer to specialize, since collaboration releases firms from additional financial 
commitments, allows them to share risks and spread sunk costs (Bougrain and Haudeville, 
2002). However, learning results in new ideas from combining experiences (Hakansson, 
1990), while inter-firm cooperation results in the exchange and dissemination of knowledge 
(Teece et al., 1990). 
Fourth, despite the huge investments on public research institutes, they are often ranked low 
as sources of information. For instance in a study on the topic, only “one third of the firms 
found the importance of government laboratories to be either moderate or very significant. 
No firm indicated that the information from universities or government laboratories was 
crucial for the innovation process”. In contrast, over 90% of innovative firms indicated that 
suppliers of components and materials are at least moderately significant sources of 
information in Denmark. Similarly, in an earlier study, DeBresson et al. (1998) found that 
universities and PRIs are cited by only an insignificant number of firms (15%) for 
collaboration.  
Institutional measures are therefore employed to foster academic-industry collaboration. 
One of this is the grant of patent incentives to researchers which is becoming increasingly 
common. In the USA, for instance, the Bayh-Doyle Act (1980) was introduced as a means to 
facilitate technology transfer from universities to industry. The Act allows universities to 
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retain proprietary rights over invention that were achieved through governmental funding, 
subject to the condition that the revenues from commercialization of such inventions must 
be shared with the individual researchers who were the original inventors. This may be a 
useful incentive, but this path has to be treaded cautiously when one talks of this in a 
developing country context. 
Funding can be used to encourage collaborative research in an effective way.  The Japanese 
government initiated several R&D programmes for biotechnology that had university-
industry linkages as a pre-condition for the selection/ funding of research projects in the 
past two decades. Through these conditions, inter-organizational interactions were promoted 
(see Hayashi, 2003). Others measures include R&D contracts, reimbursable grants and state 
R&D procurement (Inzelt, 2004). 
5. Data Sources and Variables 
The survey employed a multi-method field study approach. We collected a wide variety of 
data, which include primary, secondary, and consulted with different expert sources in 
building up the case studies that rely considerably on scientific expertise perception of 
scientists. 
The first tool was a review of existing data sources including policy documents, from the 
relevant ministries and agencies such as the S&T, agriculture and industry ministries. 
Information was collected from relatively new agencies such as the SHEDA Science and 
Technology Complex (SHESTCO). Others are the newly created National Biotechnology 
Development Agency (NABDA), and older institutions such as International Institute of 
Tropical Agriculture (IITA), International Livestock Research Institute (ILRI), University 
departments (microbiology, botany, biotechnology, molecular biology, medicine, among 
others), and the National Veterinary Research Institute (NVRI), Vom.  
The next instrument was a set of semi – structured interviews of leading experts in 
biotechnology. This exercise was necessary for two reasons. First, it helped to clarify the 
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structure and content of our framework and secondly, it was used to refine and provide 
content validation to the survey questionnaire. 
We thereafter refined the questionnaire after a pilot test it on a small portion of our sample 
largely the key informants that we had earlier identified using a list from our contacts of the 
key institutions that form our samples. We also relied extensively on the Nigeria 
biotechnology country report that was earlier prepared by NABDA in the process of this 
study. Broadly we interviewed and serve questionnaires on the following category of actors: 
• Public and International Research Institutions; 
• University departments such as microbiology, botany, virology, and so on; 
• Private firms involved in agriculture biotechnology (crop and livestock); 
• International Research Institutions; and  
• Local research institutes 
• Traditional medicine practitioners and hospitals. 
• NGOs 
• Representatives of local and indigenous communities 
In all, we retrieved 170 questionnaires and carried out face-to-face interviews with over sixty 
actors, including scientists working in universities, PRIs, firm executives, officers at 
governmental agencies and doctors/ workers at traditional health institutes and primary 
health centres. 
5.1. The Model 
The model hypothesizes a functional relation between innovation activity (the propensity to 
invent and subsequent translation into a commercial product or process) and a number of 
explanatory variables that represent the capacity of scientific organizations in which scientists 
are based. The study based on preliminary interviews focus on product innovation measured 
in terms of a discrete variable that takes a value of 1 if an organization has been involved in 
the development its OWN NEW PRODUCT. From our analytical framework, an invention 
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runs literally a gauntlet of innovation steps and the probability of reaching the market is a 
function of many factors. Again, we do not make a distinction between the possible changes 
to processes given that our domain is the scientific laboratory rather than the firm where 
continuous or incremental technical changes might take on a much more heterogeneous 
function where innovation to a product will require simultaneous alteration to process. The 
unit of analysis is the individual scientist.   
A probit analysis was undertaken to examine the determinants of probability to innovate in 
public institutions in Nigeria. Once again, the probit model used enables us to identify the 
direction of various variables on the likelihood that an institution (University or PRI) 
undertakes innovation. The model specifying the dependent and independent variables are 
defined. The propensity to, and the factors that constitute barriers to innovate in Nigeria’s 
universities and PRIs engaged biotechnology research is depicted in the probit model.  
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Where P = the probability that an institution does innovate. This was based on a simple 
question simply asked to determine whether an institution had been involved in OWN 
DEVELOPMENT OF A NEW PRODUCT.  Xi’s represents the explanatory variables 
considered. 
 
Dependent Variable:   This is based on observed innovation in an  
    organization  
 
From the survey data (on universities and PRIs), an organization is regarded as having 
undertaken innovation if in had been involved in OWN NEW PRODUCT development in 
the last 3 years.  Hence, 
 
Newprod = 1 If an organization developed a new (own)  
  product in the past 3 yrs  
    = 0 Otherwise 
 
 
Independent Variables 
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Medresearch   = 1 if an institute participates in medical   
      research  
    = 0 Otherwise 
Totalpmb                                =                      Total staff with PHD, Masters and  
            Bachelors in absolute numbers.  
 
Locdisall    = 1 if an institute spends all in research directed  
      towards local disease conditions  
    = 0 Otherwise 
 
Locdisall    = 1 if an institute spends 50 % in research  
     directed towards local disease conditions  
    = 0 Otherwise 
 
Locdisall    = 1 if an institute spends 25 % in research  
     directed towards local disease conditions  
    = 0 Otherwise 
 
Fundgovbn   = 1 If an institute obtains funding from the  
      government  
    = 0 Otherwise 
 
Forcollbn   = 1 Strong foreign links 
    = 0 Low foreign links 
 
Academiccoll   = 1 Strong academic collaborations  
    = 0 weak academic collaborations 
 
Hospitalcoll   = 1 Strong hospital collaborations  
    = 0 weak industrial collaborations 
 
Medicprccoll   = 1 Strong medical collaborations  
    = 0 weak industrial collaborations 
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Penvbiotfhi   = 1 If an institute views present biotech   
      environment as very strong  
    = 0 Otherwise 
 
 
Collaboration intensity is derived from response ratings provided in the questionnaire. The 
benchmark is “3”; that is, if an organization has a rating above “3” collaboration is regarded 
as strong and below 3 is regarded as weak/low. 
 
The strength of the institutional environment is determined taking into consideration several 
factors particularly relating to the availability of knowledge infrastructure proxied by 
Information and Communication Technology (ICT), and physical infrastructure proxied by 
power and water. The functioning of a good laboratory depends to a large extent on the last 
two factors(which is often a constraining factor in developing countries) in addition to the 
basic requirements of reagents and son on. So the average of the three factors is computed 
and if an institution had above 2 in the rank provided it is taken to mean that it viewed the 
present environment for biotechnology as strong. 
 
The other institutional factors are finance, collaborative learning (of different kinds), 
incentive systems to focus on local disease or food problems and the availability of human 
capital (PhDs and Masters level holders). The progress to the different phases of 
biotechnology research and commercia;ization is a measure of how much of the gautlet a 
laboratory ran in the rough road to market.   
5.2. Findings 
5.2.1. Descriptive Analysis 
Tables 4 and 5 show that 67% and 73.5% of universities and PRIs research efforts 
respectively are focused on screening and laboratory based product development, a finding 
that shows the dominant activities of the research centres. However there are variations 
particularly between the older universities (UI and OAU) in the Southern part of the country 
with a relatively longer history of research and the newer universities such as FUT based in 
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the North. More clinical/field trials are being undertaken in the latter universities for two 
main reasons. They have a more entrenched tradition of research and with this advantage 
greater number of well known scientists with local and international connections to other 
research centres. For the aforesaid reason they have been able to attract greater research 
funds. For instance the WHO malaria research programme is based in the medical science 
faculty at the UI, a programme that has now been expanded into a regional activity with UI, 
its hub. What this means is that commercialization of research results has not proceeded further than the 
laboratory in many instances. 
Table 6 provides a descriptive explanation of the inventive capabilities of the organizations 
based on four different variables namely, capacity for new product/process, continuous 
investment in equipment, capacity to undertake own R&D, and the capacity of the 
laboratory to undertake biotechnology activity. The four variables relate to the following 
capabilities measured against a benchmark that the scientists know: skills and knowleddge, 
financial resources, combined experience and qualification of staff, and scientific 
infrastructure respectively. The F-test shows statistical significance in three of the variables 
(except for investment in new laboratory equipment) between the PRIs but they all rate 
relatively low. The table shows a low rate of investment across the agencies confirming what 
we found during the interviews and visits to the various organizations.  
 30
Table 4: Share of university activity at different stages of the innovation process 
Institutions Screening/secondary 
screening % 
Product/proces
s development 
% 
Clinical/field 
trials % 
Current 
production 
% 
Total 
respondents 
ABU 22% 15% 4%  13% 
FUT 15% 15% 13% 23% 15% 
OAU 27% 30% 17% 23% 25% 
UI 37% 41% 65% 54% 46% 
Total 41 (10%0) 27 (10%0) 23 (100%) 13 (100%) 104 (100%) 
N=104 
 
Table 5: Stages of Research and Share of Development Activity in PRIs  
Institutions Screening 
/secondary 
screening % 
Product/process 
development % 
Clinical/field 
trials % 
Current 
production 
% 
1. NAGRAB     
2. NVRI 13.6 34.1 30.7 21.6 
3. NIPRD 57.6 15.6 12.4 14.4 
4. SHETSCO 68.3 31.7   
Total 46.4 27.1 21.5 17.5 
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Table 6: Capabilities for Process and Product Innovation  
Variables NVRI NIPRID SHETSCO Total Sig 
 New product 
development 
1.700 
(.48305) 
1.900 
(.31623) 
1.4286 
(.53452) 
1.7037 
(.46532) 
.119 
.071 
Investment in 
new 
equipment 
1.100 
(.3162) 
1.500 
(.52705) 
1.2857 
(.48795) 
1.2963 
(.46532) 
.159 
.101 
New Process 
based on in-
house R&D 
1.200 
(.42164) 
1.900 
(.31623) 
1.2857 
(.48795) 
1.4815 
(.50918) 
.002 
.000 
Rating of 
laboratory 
facilities 
3.50 
(.577) 
3.67 
(.577) 
2.25 
(.500) 
3.09 
(.931) 
.015 
.066 
 N=109 
Table 7: Local Collaboration ratings by universities 
 Firms Universities PRIs 
ABU 1.73 1.65 1.88 
FUT 2 1.64 1.99 
OAU 3.67 1.93 3.34 
UI 3.05 4.01 4.03 
 1= very low; 5= very strong; N=69 
  
 Table 8: Intensity of local and foreign collaboration index (scale 1-5) 
   InstitutionsÆ 
Type of 
collaboration 
NAGRAB NVRI NIPRID SHETSCO
Local 2.00 1.80 2.40 2.69 
Foreign 3.00 1.40 2.80 2.86 
Source: Authors survey  
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5.2.2. Empirical Results  
The results of the estimated probit model are shown in Table 9. Two models were estimated, 
model 1 and model 2. The diagnostic tests indicate that the models estimated are of good fit; 
they include Log likelihood, Likelihood ratio LR-Test and Pseudo R2. There were no 
multicolinearity or heteroscedasticity detected.  
 
Our interviews show that organizations are judged to be successful on the strength of their 
ability to solve local problems such as containing disease outbreaks or finding solutions to 
neglected diseases8. We therefore included the scientific effort and intensity of resources 
devoted to local disease problems as key factors in the models. We examine three levels of 
local disease investment (at 25%, 50% and 100% levels). The variable is coded: “Locdisall”. 
Model 1 is estimated with the three levels of disease investment which considered the 
proportion of money directed towards local disease conditions. In model 2, only one level of 
local disease investment is included. In the first model, four variables are significant and 
these are: human capital which is a composite of the holders of PhDs, Masters and bachelor 
holders (Totalpmb), Locdisall, Locdis25 and level of foreign collaboration (Forcollbn). 
Totalpmb is positive and significant at 10 percent. Locdisall and Forcollbn are both positive 
and significant at 1 percent. Locdis25 is positive and significant at 5 percent. In model 2, 
with Locdisall only, government funding (Fundgovbn) became positive and significant at 10 
percent. All the other variables remain significant except for Totalpmb which became 
insignificant. The statistical interpretation of all these results is that the probability of 
innovation increases with Totalpmb, Locdisall, Locdis25, Forcollbn and Fundgovbn in an 
organization. All the collaborative variables are not significant.  
 
                                                          
8 Two notable examples in our study are advances made by the National Veterinary Research Institute (NVRI), 
an eighty year old organization that has recorded landmark innovations in containing various animal disease 
outbreaks such as rinderpest not just in Nigeria but across West Africa. The second is the NIPRID which has 
succeeded in developing a drug for sickle cell anemia, an orphan disease. 
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Table 9: Probit Analysis with Innovation as the Dependent Variable 
Independent 
Variables 
Coefficients 
Model 1 
P-Values Coefficients
Model 2 
P-
Values 
Medresearch 0.163 
(0.287) 
0.572 0.121
(0.272)
0.656 
Totalpmb 0.054 
(0.028) 
0.056 0.039
(0.027)
0.151 
Locdisall 0.865 
(0.319) 
0.007 0.539
(0.286)
0.060 
Locdis50 0.739 
(0.494) 
0.135 - - 
Locdis25 1.325 
(0.522) 
0.011 - - 
Fundgovbn 0.430 
(0.316) 
0.173 0.502
(0.303)
0.097 
Forcollbn 0.887 
(0.305) 
0.004 0.791
(0.293)
0.007 
Academiccoll -0.215 
(0.336) 
0.523 -0.221
(0.322)
0.493 
Hospitalcoll 0.580 
(0.376) 
0.123 0.553
(0.370)
0.135 
Medicpraccoll -0.388 
(0.371) 
0.296 -0.228
(0.360)
0.527 
Penvbiotfhi -0.197 
(0.372) 
0.597 0.006
(0.358)
0.986 
Constant -1.491 
(0.315) 
0.000 -1.210
(0.278)
0.000 
No of 
Observations 
119 119  
LR–Test 37.08 
(0.00) 
29.00
(0.00)
 
Log Likelihood -61.30 -65.34  
Pseudo R2 0.23 0.18  
Note: Numbers in parentheses represent standard errors 
Source: Computed from UNU-INTECH survey 
 
 
Table 10 represents results of marginal effects on innovation. The coefficients represent the 
mean values of marginal effects. All the variables are significant and retained their signs. The 
interpretation of these variables is that if an organization increases its employment of staff 
with Ph.D., masters, and bachelors by one unit, it is likely to increase its chance of 
innovation by 0.02 points (2 %). All the other variables would be interpreted in the same 
way. For instance a investing in local disease (at different rates) Locdisall, Locdis50, 
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Locdis25, fostering foreign collaboration (Forcollbn) and increasing funding by government 
(Fundgovnbn) would have an increment of 0.329, 0.288, 0.48, 0.34 and 0.185 respectively. 
This could mean that there is considerable potential to improve for all the given variables. 
For instance, while collaborative variables were in themselves not significant, marginal 
effects analysis shows that there is scope for increased organizational performance through 
collaborative learning.  
Table 10: Marginal Effects on Innovation 
Independent Variables Marginal 
Effects 
Model 1 
P-Values Marginal 
Effects 
Model 2 
P-Values 
Medresearch 0.062
(0.109)
0.572 0.046 
(0.104) 
0.656
Totalpmb 0.020
(0.011)
0.058 0.015 
(0.011) 
0.154
Locdisall 0.329
(0.116)
0.005 0.208 
(0.110) 
0.058
Locdis50 0.288
(0.185)
0.119  
Locdis25 0.480
(0.143)
0.001  
Fundgovbn 0.159
(0.111)
0.156 0.185 
(0.107) 
0.083
Forcollbn 0.340
(0.112)
0.002 0.305 
(0.110) 
0.006
Academiccoll -0.082
(0.128)
0.523 -0.085 
(0.123) 
0.493
Hospitalcoll 0.224
(0.145)
0.122 0.214 
(0.143) 
0.134
Medicpraccoll -0.142
(0.130)
0.276 -0.086 
(0.133) 
0.518
Penvbiotfhi -0.073
(0.134)
0.587 0.002 
(0.137) 
0.986
Note: Numbers in parentheses represent standard errors 
Source: Computed from UNU-INTECH survey 
 
 
6. Case Studies 
 
This research explores a set of propositions on what constitutes barriers to translating 
inventive research and development in biotechnology to innovation in a developing context. 
A number of structural and institutional variables were included in the multivariate equation 
used, namely, the types of collaboration, the nature of funding, and the focus of investment. 
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The analysis underpinned the fact that success in biopharmaceutical research relies on 
multidisciplinary collaboration between scientists in different scientific fields as well as the 
creation of new institutions that may previously be alien to the way scientific work is carried 
out in developing countries. In this section, we present two case studies to illustrate the role 
of institutions in the in translating inventive efforts to innovation in the biopharmaceutical 
system of innovation. 
   
6.1. Institutions and Human capital: Federal University of Technology Minna 
Vaccine development 
 
The study focused on the activities of the Faculty of Biological Sciences headed by a 
professor with a long experience in animal diseases that proved useful in solving an outbreak 
of human disease epidemic. The focus of the case study is the Typhoid Fever (TF) vaccine 
developed by the faculty scientists after a major outbreak of the disease in 1992/94. The 
potential widespread implications of an unmitigated health disaster prompted the scientists 
at the Federal University of Technology Minna (FUTM) to seek a solution. In what follows, 
we narrate the process by which the group developed the vaccine and draw the necessary 
lessons. 
The scientists collected samples from local strains from infected persons and then isolated 
the organism, which is a standard procedure. But beyond this stage, they lacked the 
necessary equipment and facilities to proceed further, and therefore, sought external 
assistance. The samples were sent to a laboratory in Collendale, United Kingdom for 
characterization of the isolates. They thereafter requested for stock culture and 
simultaneously prepared stock from local strains. From this, vaccines were developed and 
they subsequently injected mice, rabbits and monkeys in that order before clinical trials were 
carried out on humans. At this point, the National Agency for Food and Drugs Control 
(NAFDAC) was informed and the Agency carried out their own independent assessment but 
suggested extensive modifications to the facilities and structures at FUTM. This might well 
be a reflection of the very poor state of the laboratories under which the scientists work. 
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About 4000 mice were used in the experiment in order to try 68 different types of vaccines 
and in the process 38 of these were eliminated. The next phase trial on rabbits eliminated all 
but 3, out of which one was found outstanding. The test outcome proved the superiority of 
local strains. 
The Typhoid vaccine project raises a number of issues, all related to institutional weaknesses. 
First, getting the research off the ground required considerable individual efforts aided by a 
confluence of institutional collaboration. The team leader is a virologist who had earlier 
spent fifteen years at the Natural Veterinary Research Institute (NVRI) before moving to the 
FUTM to start the microbiology department in 1988 motivated the research. His work at the 
NVRI was to develop animal vaccines and the competence was brought to bear on the 
development of TP vaccine for humans. NVRI and NPRID played different but important 
roles in developing the vaccine. 
The second is the funding constraint, an issue that resonated in all our interviews at all the 
institutions we visited. The process was threatened by poor funding at all phases. Obtaining 
the requisite laboratory materials and animals required a relatively significant amount of 
money, given the poor resources of the University. The scientists had no special research 
funds to draw from and at critical junctures the vaccine development process was saved by 
sheer serendipitous meeting with some individual and organizational collaboration.  
The third was the terms of employment that put the onus for patenting on the individual 
scientist. The money required was beyond the means of the scientists and the product was 
patented without assistance from the university. Needless to say, the university has no 
technology transfer office or any of its variant to help.   
Fourth, and more pervasively as far as most institutions are concerned, the facilities for 
characterizing isolates were missing. It was the chance intervention of UNIPETROL, an oil 
company that saved the process. The company paid for the transportation of the sample to 
the laboratory in the United Kingdom where the isolates was characterized. 
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Finally, although the technique was patented and vaccines were administered to over 2000 
persons within the Minna area, nothing much has been done ever since because the 
investors have no clue as to what next to do. The university as an institution can do very 
little to produce the vaccines in mass quantities and the scientists themselves are unable to 
initiate the process. In fact, little is known about this important work, which has been 
published in a number of local and international journals. 
Instead of recognizing and promoting the research potential at the FUTM, massive cuts in 
public budget to universities, has resulted in reducing the capacity of the institution to do 
quality research at the institution. The fact that FUTM has little external links and relies 
almost completely on federal funding to carry out research is reflected in the very poor if not 
non-existent follow-up efforts to the typhoid fever project. 
6.2. NIPRID and Sickle Cell Research 
 
NIPRD has a scientific and technical staff of over 75 personnel comprising pharmacists, 
clinicians, pharmacologists, clinical pharmacologists, microbiologists, chemists, molecular 
biologists, pharmacognosists, phytochemists, taxonomists, chemical engineers, 
immunologists, biochemists, information scientists, computer scientists and instrument 
technicians. The institute has a company called NIPCO Pharmaceuticals, a drug 
manufacturing outfit which carries out activities in drug manufacturing, quality control and 
product research and development. 
 
NIPRD has conducted research and development investigations on the following: 
i. Development of pharmaceutical grade starch, glycerin and kaolin using local resources 
ii. Production and quality control of pharmaceutical products from medicinal and aromatic 
plants 
iii. Documentation of indigenous medicinal and aromatic plants9; and  
                                                          
9  A Nigerian herbal pharmacopoeia was initiated at NIPRID due to the poor statistics on medicinal 
herbs. In 1990 a documentation exercise resulted in the classification of 650 medicinal plants used largely 
around the Federal Capital Territory where NIPRID is based. A joint ethobotanical survey of Bauchi State was 
also carried out jointly with the Abubakar Tafawa balewa University in Bauchi. The framework for the surveys 
had envisaged a countrywide survey in collaboration with universities based in the local areas in the hope of 
building a compedium  
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iv. Screening of indigenous medicinal plant extracts and products used widely in 
ethnomedicine for the management of sickle cell disorder, HIV/AIDS disease, malaria, 
diabetes, bacterial and fungal infections, hypertension, epilepsy, asthma, parasitic infections 
and contraception. In additional to the national compendium, the Institute has undertaken a 
limited cultivation of plants at their Medicinal Plant Garden to ensure their survival and to 
maximize the yield of active constituents from the herbs. 
The institute has developed collaboration with traditional medicine practitioners, and 
developed some drugs from indigenous plants namely,  
• NIPRISAN is a drug used for the prophylactic management of sickle cell disorder; 
• NIPRIPAN is an anti – ulcer preparation developed from Nigerian indigenous herb; 
• NIPRIFAN, a highly effective topical anti – fungal agent, was developed from a local 
plant; 
In addition to research activities, NIPRID is engaged in drug production, quality control 
services, and diagnostic consulting services. As part of these services, it has developed 
pharmaceutical grade starch from local maize up to the pilot plant stage although 
commercial production has yet to start. This is an important contribution since the country 
imports 100% of this grade of starch.  
 
However, it is the landmark research into, and discovery and production of, NIPRISAN, a 
drug used for the prophylactic management of sickle cell that seems to define the efforts of 
the Institute thus far. Information on the potency of a local medicinal plant was related to 
the then chief executive of NIPRID, Professor Charles Wambebe by a traditional healer who 
also was an Anglican reverend gentleman, and a descendant from a family of traditional 
healers. NIPRID entered into a formal contractual agreement with the healer after 
ascertaining his willingness. An important incentive for the healer was the provision in the 
agreement for the Institute to purchase the raw materials directly from the healer – this 
enabled him to make substantial earnings. The contractual stipulations also include revenues 
of 7% to NIPRID and 3% to the healer for all sales of the drug NIPRISAN. NIPRISAN has 
been developed into both capsule forms and drug syrup granules for pediatric use. Clinical 
trials of the drug were conducted between 1997 and 2002. At the time of the survey, the 
process of local certification through the NAFDAC was far advanced but incomplete.  
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An all-purpose essential oils extraction pilot plant for the production of NIPRISAN and 
other drugs was funded by the FGN, UNDP/UNIDO in the late 1990s and has been an 
essential facility despite the frequent power outages and occasional breakdowns due to the 
lack of spare parts and components. Assisted by UNIDO, the product was patented in 1998 
in the United States and initial efforts for production initiated through collaboration with a 
US-based pharmaceutical firm, Xechem, to which the NIPRISAN production was licensed. 
  
NIPRID has developed a network of collaboration with a number of domestic and 
international organizations which include the National Institute of Health, United States, 
Institute of Human Virology, Baltimore, United States (collaborative work on HIV-1 
vaccines project); Centre for Disease Control and Prevention (CDC) Atlanta, USA, the 
Robert Koch Institute, Berlin, Germany; the Council for Scientific and Industrial Research 
(CSIR), New Delhi, India; Central Drug Research Institute, Lucknow, India and the London 
School of Hygiene and Tropical Medicine, UK. Locally, NIPRID has collaborative research 
ventures with all major universities. The Institute has entered into collaborative R&D 
agreements and consultancy services with various corporate and governmental organizations 
for the supply of laboratory equipment and financing of specific research projects. For 
instance, one of the earliest research grants of US$3.5 million was made by the Japanese 
government for the procurement of research equipment, an exercise that was contracted to 
the British Crown Agent, London. The UNDP also made a grant of US$1.4 million to 
NIPRI for the project titled: “Techno-Economic Development of Medicinal and Aromatic 
Plants for Indistrial Purposes” and followed this up with a supplementary grant of US$ 
250,000 in December 1997for the purchase od equipment for the Human Virology and 
Biotechnology Department. The procurement of the equipment was contracted to UNIDO 
(Vienna).  
NIPRID has had some success but clearly has not realized its promise. The main limitations 
that have impeded progress for NIPRID, FUTM and the other PRIs and universities visited 
could be summed up as follows: 
• Institutional constraints that lead to poor funding and sebsequent lack of facilities 
for biotechnology-based research. 
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• Lack of institutional infrastructure to conclude meaningful partnerships with holders 
of traditional medicinal knowledge and to contract in states of drug development.  
• Lack of regulatory mechanisms to test for efficacy and safety of traditional 
preparations. 
• Institutional rigidities that undermine interaction between universities, public 
research institutes and agencies that possess the mandate to commercialize drugs 
based on traditional knowledge, such as NIPRID. 
• Lack of private sector interest in drug development: presently, most of universites 
and PRIs research (90%) focuses on screening and secondary screening, with only a 
last 10% focus on product development activities. Large pharmaceutical firms in 
Nigeria show little interest and new technology-based firms are yet to fill this gap. 
• Lack of governmental aid in conducting research: presently, 90% of their research 
funds are from international sources, with only 10% from the Nigerian government. 
The grant money is used to purchase laboratory equipment and chemical agents that 
are required for conducting research. 
• Lack of foreign research collaborations that may help scientific and technological 
capacity building: 
Presently, except for grants, there are no systematic capacity building partnerships with 
foreign partners despite efforts by various research the teams. Long term commitment by 
the government will be the more effective solution while grants and aids supplement.  
7. Conclusions 
In the foregoing analysis, we have employed both qualitative and quantitative approaches to 
understand the nature of interactions that lead to translating research into innovation. Four 
major factors condition the competencies of actors in any given system of innovation in 
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translating inventions into innovations: national innovation policies, learning efficiency of 
actors, mechanisms available to translate products and processes into the local markets and 
the innovation orientation of actors. The presence or absence of institutions (or the 
inadequacy thereof), in turn, are central to how these competencies emerge over time. We 
have considered two broad ways in which institutions end up constituting systemic 
institutional barriers to the process of innovation, instead of alleviating them. This is linked 
to the ability of institutions to provide incentives for innovation and for infrastructural 
facilities in certain science-based technologies, and the ability of institutions to enable 
collaborative learning. The lack of such basic-yet-critical endowments can hinder capacity 
from developing in biopharmaceutical research, despite the fact that there are several 
pockets of excellence in this area within Nigeria. The paper has used the case of PRI and 
university capacity to come up with new innovative products and processes to demonstrate 
this. A variety of variables that play a significant role in promoting innovation in 
biopharmaceutical research have been considered, and their marginal effects have been 
calculated. 
 
The data collected in Nigeria confirms our analysis on the factors that cause systemic 
disarticulation and weak collaboration. All organizations survryed have sought collaboration 
and those that are presently not doing so, express the desire for both local and international 
partnerships. They are clearly limited by the systemic factors that do not lay weight on 
promoting collaboration, lack of interest amongst some/ many sets of actors, like the private 
sector, and policies that do not view collaboration in a dynamic perspective. Secondly, there 
is also a lack of institutional incentives. The institutions in which scientists work hardly 
reward entrepreneurship and there is no motivation to make additional effort beyond 
publication of academic papers. Most academics do not understand the institution of patents 
for instance and have had little guide as to what to do to move inventions to the market. 
Moreover, the sheer weight of infrastructural constraints leaves them with very little energy 
to think beyond their immediate concerns. The concerns with short term goals was evident 
and long term commercialization efforts was down the priority list of scientists. It was 
evident to the research groups that major institutional shifts would be required to change the 
present habits and practices of the PRIs. While individual researchers are able to carry on 
working up to a point, the odds rise dramatically as projects demand better facilities, skills 
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and knowledge that the lone scientist could offer.  The lack of infrastructure facilities 
compounds this issue further. Formal institutional arrangements which we find missing in 
almost all cases would then be required. This also leads us to conclude that collaborative 
efforts are inevitable between the different PRIs and with external technical partners. Our 
interviews show that collaboration has been limited by three main factors, namely, the 
inability of scientists to move their work beyond the individual organizations; the absence of 
formal institutions supporting collaboration; and, poor incentive to motivate scientists. 
On the question of learning and obstacles to the innovation process, three point seem 
pertinent. First, an understanding of the process gives an insight into the motives and limits 
of the organizations capacity. Second, it provides some clue into the nature of the value that 
an organization is able to add to the natural starting material given that biopharmaceutical 
remains one of the few activities that tend to follow the linear technology-push model 
whereby products follow almost directly from invention to prototype to the market, Trott 
(1998). Third, the nature of activity and the locus of the organization’s work in the process 
may also suggest to the relevance and the perceived importance of the product by the 
market. For instance, in this study we find that several research projects remain at incipient 
stages.  
Our analysis of the innovation process for biopharmaceutical research within Nigeria reveals 
specific obstacles at different stages of work that the institutions were engaged in, for three 
reasons. First, lack of facilities and financing to move the research to the concluding stages. 
Second, we found situations where significant research results had been collected, with 
evidence of possible utility of the process and product, but no demand by the end-users10. 
Third, failure to commercialize sometime resulting from institutional rigidity much of which 
relates to the ways traditional PRIs and universities are set up. There are two issues that 
recurred in our interviews namely, who initiate the process (the PRI or a 
firm/entrepreneur?); and what form of formal or informal contract guides the process? In 
advanced developing and highly industrialized countries, two broad types of formal contract 
                                                          
10 As Jolly, (1997) observed, technologies and for that products and process inventions fail not so much for 
the skills of the inventor and the lack of market but because no one promotes or get sufficiently interested in 
them.   
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are common, which are, academic entrepreneurship, and spin-off companies from public 
research or universities.11         
Across the different PRIs, major efforts and resources seem to be concentrated at the early 
stages of drug development, which is screening and secondary screening (30% to 68.3%). As 
such there is no statistically significant difference between institutes, meaning that all the 
PRIs are engaged uniformly in this activity. However, at the next level, which is 
process/product development/field trial, we find significant difference while only two of the 
institute, NVRI and NIPRID are involved in production activity. For instance, NIPRID 
produces the anti- sickle cell drug called Niprisan while NVRI is involved in vaccine 
production, albeit on a limited basis for regional and national clients. Understandably, 
SHETSCO being a fairly young establishment is not involved in any form of production.  
 
                                                          
11 Academic entrepreneurship takes several forms namely; (a) Involvement in large-scale externally funded 
research, (b) consultancy to earn supplementary income; (c) university-industry research and transfer of 
technology, (d) patents and trade secrets, and (e) commercialization which might involve holding equity in 
private enterprises by scientists, see Altonen, M. (1998).  
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